FGF23 Expression Is a Promising Immunohistochemical Diagnostic Marker for Undifferentiated Pleomorphic Sarcoma of Bone (UPSb)
Open Access
Abstract
Background: Undifferentiated pleomorphic sarcoma of bone (UPSb) is a rare primary bone sarcoma that lacks a specific line of differentiation. Distinguishing between UPSb and other malignant bone sarcomas, including dedifferentiated chondrosarcoma and osteosarcoma, is challenging due to their overlapping features. We have previously identified that UPSb tumours have elevated mRNA levels of Fibroblast Growth Factor 23 (FGF23) transcripts compared to other sarcomas including osteosarcoma. In the present study, we evaluated the specificity and practicality of FGF23 immunoreactivity as a specific diagnostic tool to differentiate UPSb tumours from osteosarcomas and dedifferentiated chondrosarcomas. Methods: A total of 10 UPSb, 10 osteosarcoma, and 10 dedifferentiated chondrosarcoma cases (all high-grade), were retrieved and immunohistochemistry for FGF23 was performed. Results: FGF23 protein was expressed at high levels in 80–90% of undifferentiated pleomorphic sarcoma of the bone cases, whereas it was expressed at significantly lower levels in dedifferentiated chondrosarcoma and osteosarcoma cases. A semiquantitative analysis, considering the intensity of immunoreactivity, confirmed significantly elevated FGF23 expression levels in UPSb tissues compared to those observed in osteosarcoma and dedifferentiated chondrosarcoma tissues. Conclusions: The results we present here suggest that FGF23 immunohistochemistry may be a useful tool to aid in differentiating UPSb from morphologically similar malignant bone sarcomas, especially in situations where sampling is restricted and there is limited clinical information available.Keywords
Funding Information
- Bone Cancer Research Trust (BCRT) (BCRT/7020, Ricerca Corrente L4097 and L4135)
- Kuwait Medical Genetics Centre (KMGC), Ministry of Health, Kuwait (BCRT/7020, Ricerca Corrente L4097 and L4135)
- Italian Ministry of Health (BCRT/7020, Ricerca Corrente L4097 and L4135)
- Rotha Abraham Bequest, New Cross Hospital, Wolverhampton, UK (BCRT/7020, Ricerca Corrente L4097 and L4135)
This publication has 38 references indexed in Scilit:
- Immunohistochemical and molecular detection of the expression of FGF23 in phosphaturic mesenchymal tumors including the non-phosphaturic variantDiagnostic Pathology, 2016
- Fibroblast growth factor 23 and bone mineralisationInternational Journal of Oral Science, 2015
- Clinical outcome for patients with dedifferentiated chondrosarcoma: a report of 9 cases at a single instituteJournal of Orthopaedic Surgery and Research, 2012
- Fibroblast Growth Factor 23 (FGF23) and Alpha-Klotho Stimulate Osteoblastic MC3T3.E1 Cell Proliferation and Inhibit MineralizationCalcified Tissue International, 2011
- Genetic Evidence of Serum Phosphate-Independent Functions of FGF-23 on BonePLOS Genetics, 2008
- Overexpression of Fibroblast Growth Factor 23 Suppresses Osteoblast Differentiation and Matrix Mineralization In VitroJournal of Bone and Mineral Research, 2008
- Elevated Fibroblast Growth Factor 23 in Women With Malignant Ovarian TumorsMayo Clinic Proceedings, 2005
- Fibroblast Growth Factor 23: A New Clinical Marker for Oncogenic OsteomalaciaThe Journal of Clinical Endocrinology & Metabolism, 2003
- Etiology of OsteosarcomaClinical Orthopaedics and Related Research, 2002
- Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalaciaProceedings of the National Academy of Sciences, 2001